Medication precautions for the targeted drug brigatinib

Brigatinib (Brigatinib) is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC), especially patients with anaplastic lymphoma kinase (ALK)-positive mutations. Although Brigatinib is excellent in treatingALKpositiveNSCLC, there are many considerations when using this drug to ensure its safety and efficacy. The following are key points to note when taking brigatinib (brigatinib) .

1.Starting dose and dose adjustment

The recommended starting dose of brigatinib is 90 mg once daily for 7 days. If the patient is able to tolerate the dose, the doctor will increase the dose to 180 mg once daily, which is the usual maintenance dose. Patients should take brigatinib (brigatinib) in strict accordance with the doctor's instructions and are not allowed to change the dose or stop the medication without authorization. Abrupt discontinuation may result in rapid disease progression, and inappropriate dose adjustment may increase the risk of adverse effects.

2.How to take medicine

Brigatinib tablets may be taken with or without food, but they must be swallowed whole and not chewed, crushed, or divided. The medication time should be fixed at the same time every day as much as possible to maintain the stability of blood drug concentration. If the patient misses a dose, it should be taken as soon as possible, but if it is close to the time of the next dose, the missed dose should be skipped and the missed dose should not be doubled.

3.Common adverse reactions

Common adverse reactions of brigatinib include gastrointestinal reactions (such as nausea, diarrhea, vomiting), hypertension, visual disturbances, fatigue, decreased appetite, and rash. Patients should pay close attention to these adverse reactions while taking the medicine and report them to their doctors in time. Your doctor may adjust the dose or take other measures based on the severity of the adverse reaction.

4.Serious adverse reactions and monitoring

Brigatinib may cause serious adverse reactions, such as interstitial lung disease (ILD), hypertensive crisis, bradycardia, pancreatitis, and hyperglycemia. Patients should undergo regular medical examinations during the medication period, including imaging examinations, electrocardiograms, blood pressure monitoring and blood tests, to detect and deal with these serious adverse reactions early. If you have difficulty breathing, severe chest pain, severe headache, significant changes in vision, or other serious symptoms, seek medical attention immediately.

5.Drug interactions

Brigatinib may interact with other drugs, affecting their efficacy and safety. Patients should report all medications they are taking while taking brigatinib to their doctor, including prescription drugs, over-the-counter drugs, herbal remedies, and supplements. In particular, some strong CYP3A4 inhibitors or inducers, such as ketoconazole, rifampicin, St. John's wort, etc., may significantly affect the metabolism of brigatinib (brigatinib) and require special attention and dose adjustment.

6.Medicine Contraindications

This drug is contraindicated in patients who are allergic to brigatinib or any of its components. In addition, Brigatinib may cause harm to the fetus and should be avoided by pregnant women or women planning to become pregnant. Patients should use effective contraceptive measures to avoid pregnancy while taking brigatinib. If a patient becomes pregnant while taking this medication, the doctor should be informed immediately and treatment should be discontinued.

7.Medicine precautions for special groups

Elderly patients and patients with hepatic or renal insufficiency require special caution when using brigatinib . Elderly patients may be less tolerant to the drug and need to be closely monitored for adverse reactions. Patients with hepatic or renal impairment may require dosage adjustments to avoid excessive accumulation of the drug in the body.

8.Withdrawal and replacement therapy

In some cases, patients may need to discontinue brigatinib (brigatinib) , such as intolerable serious adverse reactions or disease progression. Discontinuation of medication should be done under the guidance of a doctor to avoid sudden discontinuation of medication. If treatment with brigatinib fails or is not tolerated, your doctor may consider other alternative treatments, such as otherALKinhibitors or chemotherapy.

9.Patient education and follow-up

Patients should receive detailed drug education before starting brigatinib treatment, including the drug's mechanism of action, possible adverse reactions, medication methods and precautions. During treatment, patients should follow up regularly to communicate with their doctor about treatment progress and any uncomfortable symptoms. The efficacy and safety of brigatinib can be maximized through close follow-up and management.

Brigatinib (Brigatinib) As an effectiveALKpositiveNSCLC treatment drug, many things need to be paid attention to during its use. Patients should take medications strictly in accordance with medical instructions, undergo regular medical examinations, closely monitor adverse reactions, and maintain good communication with their doctors. Only in this way can we ensure the safety and effectiveness of brigatinib treatment and bring maximum therapeutic benefits to patients.